Therapies for dopaminergic‐induced dyskinesias in parkinson disease
Identifieur interne : 000119 ( Main/Corpus ); précédent : 000118; suivant : 000120Therapies for dopaminergic‐induced dyskinesias in parkinson disease
Auteurs : Mildred D. Gottwald ; Michael J. AminoffSource :
- Annals of Neurology [ 0364-5134 ] ; 2011-06.
Abstract
Existing and emerging strategies for managing L‐dopa–induced dyskinesias (LIDs) in patients with Parkinson disease have involved either delaying the introduction of L‐dopa therapy, treatment with an antidyskinetic agent, using a therapy or delivery system that can provide continuous dopaminergic stimulation, or using novel agents that target receptors implicated in the mechanisms underlying LIDs. Treatment with dopamine agonists such as pramipexole or ropinirole allows levodopa to be delayed, but once levodopa is added to the drug regimen the usual course of onset of dyskinesias is observed. Amantadine, an N‐methyl‐D‐aspartate antagonist, is so far the only approved compound with evidence of providing a sustained antidyskinetic benefit in the absence of unacceptable side effects. These findings support the hypothesis of glutamate overactivity in the development of dyskinesias. More continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions. As a result of molecular research and elucidation of the role of a variety of neurotransmitters in the mechanism of LIDs, new compounds have been identified, including those that modulate the direct and indirect striatal output pathways; some of these new agents are in the early stages of development or undergoing proof‐of‐concept evaluation as antidyskinetic agents. Ann Neurol 2011;69:919–927
Url:
DOI: 10.1002/ana.22423
Links to Exploration step
ISTEX:0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapies for dopaminergic‐induced dyskinesias in parkinson disease</title><author><name sortKey="Gottwald, Mildred D" sort="Gottwald, Mildred D" uniqKey="Gottwald M" first="Mildred D." last="Gottwald">Mildred D. Gottwald</name><affiliation><mods:affiliation>Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA</mods:affiliation></affiliation></author><author><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J." last="Aminoff">Michael J. Aminoff</name><affiliation><mods:affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/ana.22423</idno><idno type="url">https://api.istex.fr/document/0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000119</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapies for dopaminergic‐induced dyskinesias in parkinson disease</title><author><name sortKey="Gottwald, Mildred D" sort="Gottwald, Mildred D" uniqKey="Gottwald M" first="Mildred D." last="Gottwald">Mildred D. Gottwald</name><affiliation><mods:affiliation>Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA</mods:affiliation></affiliation></author><author><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J." last="Aminoff">Michael J. Aminoff</name><affiliation><mods:affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-06">2011-06</date><biblScope unit="volume">69</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="919">919</biblScope><biblScope unit="page" to="927">927</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9</idno><idno type="DOI">10.1002/ana.22423</idno><idno type="ArticleID">ANA22423</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Existing and emerging strategies for managing L‐dopa–induced dyskinesias (LIDs) in patients with Parkinson disease have involved either delaying the introduction of L‐dopa therapy, treatment with an antidyskinetic agent, using a therapy or delivery system that can provide continuous dopaminergic stimulation, or using novel agents that target receptors implicated in the mechanisms underlying LIDs. Treatment with dopamine agonists such as pramipexole or ropinirole allows levodopa to be delayed, but once levodopa is added to the drug regimen the usual course of onset of dyskinesias is observed. Amantadine, an N‐methyl‐D‐aspartate antagonist, is so far the only approved compound with evidence of providing a sustained antidyskinetic benefit in the absence of unacceptable side effects. These findings support the hypothesis of glutamate overactivity in the development of dyskinesias. More continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions. As a result of molecular research and elucidation of the role of a variety of neurotransmitters in the mechanism of LIDs, new compounds have been identified, including those that modulate the direct and indirect striatal output pathways; some of these new agents are in the early stages of development or undergoing proof‐of‐concept evaluation as antidyskinetic agents. Ann Neurol 2011;69:919–927</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Mildred D. Gottwald PharmD</name><affiliations><json:string>Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA</json:string></affiliations></json:item><json:item><name>Michael J. Aminoff MD, DSc, FRCP</name><affiliations><json:string>Department of Neurology, University of California, San Francisco, San Francisco, CA</json:string></affiliations></json:item></author><articleId><json:string>ANA22423</json:string></articleId><language><json:string>eng</json:string></language><abstract>Existing and emerging strategies for managing L‐dopa–induced dyskinesias (LIDs) in patients with Parkinson disease have involved either delaying the introduction of L‐dopa therapy, treatment with an antidyskinetic agent, using a therapy or delivery system that can provide continuous dopaminergic stimulation, or using novel agents that target receptors implicated in the mechanisms underlying LIDs. Treatment with dopamine agonists such as pramipexole or ropinirole allows levodopa to be delayed, but once levodopa is added to the drug regimen the usual course of onset of dyskinesias is observed. Amantadine, an N‐methyl‐D‐aspartate antagonist, is so far the only approved compound with evidence of providing a sustained antidyskinetic benefit in the absence of unacceptable side effects. These findings support the hypothesis of glutamate overactivity in the development of dyskinesias. More continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions. As a result of molecular research and elucidation of the role of a variety of neurotransmitters in the mechanism of LIDs, new compounds have been identified, including those that modulate the direct and indirect striatal output pathways; some of these new agents are in the early stages of development or undergoing proof‐of‐concept evaluation as antidyskinetic agents. Ann Neurol 2011;69:919–927</abstract><qualityIndicators><score>7.472</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 801 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1467</abstractCharCount><pdfWordCount>5798</pdfWordCount><pdfCharCount>39838</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>206</abstractWordCount></qualityIndicators><title>Therapies for dopaminergic‐induced dyskinesias in parkinson disease</title><genre><json:string>article</json:string></genre><host><volume>69</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>9</total><last>927</last><first>919</first></pages><issn><json:string>0364-5134</json:string></issn><issue>6</issue><subject><json:item><value>Point of View</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/ana.22423</json:string></doi><id>0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Therapies for dopaminergic‐induced dyskinesias in parkinson disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Therapies for dopaminergic‐induced dyskinesias in parkinson disease</title><author><persName><forename type="first">Mildred D.</forename><surname>Gottwald</surname></persName><roleName type="degree">PharmD</roleName><affiliation>Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA</affiliation></author><author><persName><forename type="first">Michael J.</forename><surname>Aminoff</surname></persName><roleName type="degree">MD, DSc, FRCP</roleName><note type="correspondence"><p>Correspondence: 505 Parnassus Ave, Room 795‐M, San Francisco, CA 94143‐0114</p></note><affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-06"></date><biblScope unit="volume">69</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="919">919</biblScope><biblScope unit="page" to="927">927</biblScope></imprint></monogr><idno type="istex">0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9</idno><idno type="DOI">10.1002/ana.22423</idno><idno type="ArticleID">ANA22423</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Existing and emerging strategies for managing L‐dopa–induced dyskinesias (LIDs) in patients with Parkinson disease have involved either delaying the introduction of L‐dopa therapy, treatment with an antidyskinetic agent, using a therapy or delivery system that can provide continuous dopaminergic stimulation, or using novel agents that target receptors implicated in the mechanisms underlying LIDs. Treatment with dopamine agonists such as pramipexole or ropinirole allows levodopa to be delayed, but once levodopa is added to the drug regimen the usual course of onset of dyskinesias is observed. Amantadine, an N‐methyl‐D‐aspartate antagonist, is so far the only approved compound with evidence of providing a sustained antidyskinetic benefit in the absence of unacceptable side effects. These findings support the hypothesis of glutamate overactivity in the development of dyskinesias. More continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions. As a result of molecular research and elucidation of the role of a variety of neurotransmitters in the mechanism of LIDs, new compounds have been identified, including those that modulate the direct and indirect striatal output pathways; some of these new agents are in the early stages of development or undergoing proof‐of‐concept evaluation as antidyskinetic agents. Ann Neurol 2011;69:919–927</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Point of View</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-09-29">Received</change><change when="2011-03-04">Registration</change><change when="2011-06">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/ana.v69.6</doi><numberingGroup><numbering type="journalVolume" number="69">69</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2011-06">June 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="80" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.22423</doi><idGroup><id type="unit" value="ANA22423"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Point of View</title><title type="tocHeading1">Point of View</title></titleGroup><copyright ownership="publisher">Copyright © 2011 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="2010-09-29"></event><event type="manuscriptRevised" date="2011-02-25"></event><event type="manuscriptAccepted" date="2011-03-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2012-02-06"></event><event type="publishedOnlineAccepted" date="2011-03-16"></event><event type="publishedOnlineFinalForm" date="2011-06-16"></event><event type="firstOnline" date="2011-06-16"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">919</numbering><numbering type="pageLast">927</numbering></numberingGroup><correspondenceTo>505 Parnassus Ave, Room 795‐M, San Francisco, CA 94143‐0114</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA22423.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="76"></count><count type="wordTotal" number="6947"></count></countGroup><titleGroup><title type="main" xml:lang="en">Therapies for dopaminergic‐induced dyskinesias in parkinson disease</title><title type="short" xml:lang="en">DA‐Induced Dyskinesias in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Mildred D.</givenNames><familyName>Gottwald</familyName><degrees>PharmD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2" corresponding="yes"><personName><givenNames>Michael J.</givenNames><familyName>Aminoff</familyName><degrees>MD, DSc, FRCP</degrees></personName><contactDetails><email>AminoffM@neurology.ucsf.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Existing and emerging strategies for managing L‐dopa–induced dyskinesias (LIDs) in patients with Parkinson disease have involved either delaying the introduction of L‐dopa therapy, treatment with an antidyskinetic agent, using a therapy or delivery system that can provide continuous dopaminergic stimulation, or using novel agents that target receptors implicated in the mechanisms underlying LIDs. Treatment with dopamine agonists such as pramipexole or ropinirole allows levodopa to be delayed, but once levodopa is added to the drug regimen the usual course of onset of dyskinesias is observed. Amantadine, an N‐methyl‐<sc>D</sc>‐aspartate antagonist, is so far the only approved compound with evidence of providing a sustained antidyskinetic benefit in the absence of unacceptable side effects. These findings support the hypothesis of glutamate overactivity in the development of dyskinesias. More continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions. As a result of molecular research and elucidation of the role of a variety of neurotransmitters in the mechanism of LIDs, new compounds have been identified, including those that modulate the direct and indirect striatal output pathways; some of these new agents are in the early stages of development or undergoing proof‐of‐concept evaluation as antidyskinetic agents. Ann Neurol 2011;69:919–927</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Therapies for dopaminergic‐induced dyskinesias in parkinson disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>DA‐Induced Dyskinesias in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Therapies for dopaminergic‐induced dyskinesias in parkinson disease</title></titleInfo><name type="personal"><namePart type="given">Mildred D.</namePart><namePart type="family">Gottwald</namePart><namePart type="termsOfAddress">PharmD</namePart><affiliation>Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael J.</namePart><namePart type="family">Aminoff</namePart><namePart type="termsOfAddress">MD, DSc, FRCP</namePart><affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA</affiliation><description>Correspondence: 505 Parnassus Ave, Room 795‐M, San Francisco, CA 94143‐0114</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-06</dateIssued><dateCaptured encoding="w3cdtf">2010-09-29</dateCaptured><dateValid encoding="w3cdtf">2011-03-04</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="references">76</extent><extent unit="words">6947</extent></physicalDescription><abstract lang="en">Existing and emerging strategies for managing L‐dopa–induced dyskinesias (LIDs) in patients with Parkinson disease have involved either delaying the introduction of L‐dopa therapy, treatment with an antidyskinetic agent, using a therapy or delivery system that can provide continuous dopaminergic stimulation, or using novel agents that target receptors implicated in the mechanisms underlying LIDs. Treatment with dopamine agonists such as pramipexole or ropinirole allows levodopa to be delayed, but once levodopa is added to the drug regimen the usual course of onset of dyskinesias is observed. Amantadine, an N‐methyl‐D‐aspartate antagonist, is so far the only approved compound with evidence of providing a sustained antidyskinetic benefit in the absence of unacceptable side effects. These findings support the hypothesis of glutamate overactivity in the development of dyskinesias. More continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions. As a result of molecular research and elucidation of the role of a variety of neurotransmitters in the mechanism of LIDs, new compounds have been identified, including those that modulate the direct and indirect striatal output pathways; some of these new agents are in the early stages of development or undergoing proof‐of‐concept evaluation as antidyskinetic agents. Ann Neurol 2011;69:919–927</abstract><relatedItem type="host"><titleInfo><title>Annals of Neurology</title></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Point of View</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>919</start><end>927</end><total>9</total></extent></part></relatedItem><identifier type="istex">0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9</identifier><identifier type="DOI">10.1002/ana.22423</identifier><identifier type="ArticleID">ANA22423</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000119 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000119 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:0C3AAA90A055EBE51C8FD2D3E7FD2BC4D9CE35F9
|texte= Therapies for dopaminergic‐induced dyskinesias in parkinson disease
}}
| This area was generated with Dilib version V0.6.23. |  |